Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3547)
All Articles published online
|
Oct 27, 2011 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatology 2011; 3(10): 265-267 [PMID: 22059109 DOI: 10.4254/wjh.v3.i10.265] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v3/i10/265.htm |
| Number | Citing Articles |
| 1 |
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17 doi: 10.1016/j.metabol.2017.02.014
|
| 2 |
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
|
| 3 |
Rhema Khairnar, Md Asrarul Islam, Joshua Fleishman, Sunil Kumar. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sciences 2023; 312: 121185 doi: 10.1016/j.lfs.2022.121185
|
| 4 |
Satoru Matsuda, Mayumi Kobayashi, Yasuko Kitagishi. Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease. ISRN Endocrinology 2013; 2013: 1 doi: 10.1155/2013/472432
|
| 5 |
Amirhossein Sahebkar, Gerard T Chew, Gerald F Watts. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014; 15(4): 493 doi: 10.1517/14656566.2014.876992
|
| 6 |
Michael S Kostapanos, Anastazia Kei, Moses S Elisaf. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 2013; 5(9): 470-478 doi: 10.4254/wjh.v5.i9.470
|
| 7 |
T. D. Filippatos, M. Florentin, M. Georgoula, M. S. Elisaf. Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 2017; 10(2): 187 doi: 10.1080/17512433.2017.1263565
|
| 8 |
Raghdaa Al Zarzour, Mariam Ahmad, Mohd. Asmawi, Gurjeet Kaur, Mohammed Saeed, Majed Al-Mansoub, Sultan Saghir, Nasiba Usman, Dhamraa Al-Dulaimi, Mun Yam. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague–Dawley Rats. Nutrients 2017; 9(7): 766 doi: 10.3390/nu9070766
|
| 9 |
Urmi Mukherjee, Sudipta Maitra. Impact of Metabolic disrupting chemicals on redox homeostasis, energy sensors, receptor modulation, and hormone metabolism: A comparative account in Teleost and mammalian model organisms. Aquaculture and Fisheries 2024; 9(3): 455 doi: 10.1016/j.aaf.2023.05.004
|
| 10 |
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos, Moses S. Elisaf. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012; 61(7): 906 doi: 10.1016/j.metabol.2011.12.002
|
| 11 |
Jessica Mwinyi, Adrian E. Boström, Claudia Pisanu, Susan K. Murphy, Wiebke Erhart, Clemens Schafmayer, Jochen Hampe, Cynthia Moylan, Helgi B. Schiöth. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2017; 1862(3): 314 doi: 10.1016/j.bbalip.2016.12.005
|
| 12 |
Atheer Majid Rashid Al-Juhaishi, Ahmed H. Ismael, Aziz H. Jasim, Entisar J. Al-Mukhtar. Hepatoprotective Activity of Ezetimibe Against Risperidone-Induced Liver Injury in Rats. Medical Journal of Babylon 2024; 21(2): 431 doi: 10.4103/MJBL.MJBL_1510_23
|
| 13 |
Reem Abou Assi, Ibrahim M. Abdulbaqi, Chan Siok Yee. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals 2021; 14(3): 215 doi: 10.3390/ph14030215
|
| 14 |
Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti, Giulio Marchesini. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014; 18(1): 73 doi: 10.1016/j.cld.2013.09.005
|
| 15 |
Rehab F. Abdel-Rahman. Non-alcoholic fatty liver disease. Asian Pacific Journal of Tropical Biomedicine 2022; 12(3): 99 doi: 10.4103/2221-1691.338919
|
| 16 |
Theodosios D. Filippatos, Moses S. Elisaf. Statin–Ezetimibe Combination Therapy In Diabetic Individuals. Angiology 2016; 67(6): 507 doi: 10.1177/0003319715598887
|
| 17 |
Anastazia A. Kei, Theodosios D. Filippatos, Moses S. Elisaf. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 2016; 15(4): 559 doi: 10.1517/14740338.2016.1157164
|